旧问题的新转折：COVID-19 和特发性肺纤维化。
New twist to an old problem: COVID-19 and idiopathic pulmonary fibrosis.
机构信息
Department of Pulmonary Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.
All India Institute of Medical Sciences, Jodhpur, India.
出版信息
Adv Respir Med. 2021;89(1):84-85. doi: 10.5603/ARM.a2020.0177. Epub 2021 Jan 20.
Iidiopathic pulmonary fibrosis (IPF) diagnosis and treatment during this COVID-19 pandemic have been affected. COVID-19 has not only impacted the prognosis of these patients but also the approach to these patients. Pulmonary function tests (PFT) and lung biopsies are less encouraged now. Traditional antifibrotics used in IPF should be encouraged irrespective of patient lung function and in those with non-definite usual interstitial pneumonia in high resolution computed tomography.
特发性肺纤维化（IPF）在 COVID-19 大流行期间的诊断和治疗受到了影响。COVID-19 不仅影响了这些患者的预后，也影响了对这些患者的治疗方法。现在不太鼓励进行肺功能测试（PFT）和肺活检。应鼓励使用传统的 IPF 抗纤维化药物，而不论患者的肺功能如何，以及在高分辨率计算机断层扫描中无明确寻常型间质性肺炎的患者。
Zotero 插件